Congo to use Ebola vaccine to counter flare-up

Four people have tested positive for Ebola


Democratic Republic of Congo (DRC) officials say they will start using Ebola vaccine to counter a flare-up in the heavily populated eastern part of the Central African country, according to an article on the Reuters website.

Four people have tested positive for Ebola in and around Mangina, a town of about 60,000 people in North Kivu province, about 60 miles) from the Ugandan border.  

Another 20 people died from unidentified hemorrhagic fevers in July. The World Health Organization (WHO) declared the ninth outbreak of Ebola in the Democratic Republic of the Congo (DRC) over on July 24, according to an article on WHO website. 

Unlike previous DRC Ebola outbreaks, this one involved four locations, including an urban center with river connections to the capital and to neighboring countries, as well as remote rainforest villages.

Read the article.

 

 



August 7, 2018


Topic Area: Infection Control


Recent Posts

The Future of the Global Hospital Hygiene Market

A market study details the current state of the global hygiene market and the factors that are expected to make a big difference in the next decade.


Rethinking Fire Safety Inspections

Digital tools bridge the gap between growing facility complexity and workforce limitations, allowing teams to maintain the highest safety standards.


The Ohio State University Wexner Medical Center Officially Opens

With the new hospital comes other changes, including new street and building names on the medical campus.


Healthcare and Resilience: A Pledge for Change

Climate resilience and reducing environmental impact drive voluntary program targeting hospitals.


Texas Health Resources Announces New Hospital for North McKinney

Expected to open in 2028, the hospital will feature 60 beds initially with plans to double in capacity to accommodate for future community growth.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.